Blockade of AKT activation in prostate cancer cells with a small molecule inhibitor, 9-chloro-2-methylellipticinium acetate (CMEP)

Biochemical Pharmacology

Volumn 73, Issue 1, 2007, Pages 15-24

  Zhang, Manchao ^a   Fang, Xueliang ^b   Liu, Hongpeng ^b   Wang, Shaomeng ^b   Yang, Dajun ^b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

AKT; Apoptosis; Prostate cancer; Small molecule

Indexed keywords

9 CHLORO 2 METHYLELLIPTICINIUM ACETATE; MITOGEN ACTIVATED PROTEIN KINASE; NSC 632855; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN AKT 3; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN KINASE INHIBITOR; S6 KINASE; SERINE; THREONINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CELL STRAIN LNCAP; CELL SURVIVAL; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE MUTATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; CULTURE MEDIA, SERUM-FREE; ELLIPTICINES; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; MALE; MICE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 33845211696     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.07.034     Document Type: Article

References (56)

1. Chan T.O., Rittenhouse S.E., and Tsichlis P.N. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem 68 (1999) 965-1014
2. Brodbeck D., Cron P., and Hemmings B.A. A human protein kinase B gamma with regulatory phosphorylation sites in the activation loop and in the C-terminal hydrophobic domain. J Biol Chem 274 14 (1999) 9133-9136
3. Masure S., Haefner B., Wesselink J.J., Hoefnagel E., Mortier E., Verhasselt P., et al. Molecular cloning, expression and characterization of the human serine/threonine kinase Akt-3. Eur J Biochem 265 1 (1999) 353-360
4. Nakatani K., Sakaue H., Thompson D.A., Weigel R.J., and Roth R.A. Identification of a human Akt3 (protein kinase B gamma) which contains the regulatory serine phosphorylation site. Biochem Biophys Res Commun 257 3 (1999) 906-910
5. Alessi D.R., James S.R., Downes C.P., Holmes A.B., Gaffney P.R., Reese C.B., et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha. Curr Biol 7 4 (1997) 261-269
6. Vanhaesebroeck B., and Alessi D.R. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 346 Pt 3 (2000) 561-576
7. Meyers F.J., Gumerlock P.H., Chi S.G., Borchers H., Deitch A.D., and deVere White R.W. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer 83 12 (1998) 2534-2539
8. Maehama T., and Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273 22 (1998) 3375-3378
9. Damen J.E., Liu L., Rosten P., Humphries R.K., Jefferson A.B., Majerus P.W., et al. The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase. Proc Natl Acad Sci USA 93 4 (1996) 1689-1693
10. Kavanaugh W.M., Pot D.A., Chin S.M., Deuter-Reinhard M., Jefferson A.B., Norris F.A., et al. Multiple forms of an inositol polyphosphate 5-phosphatase form signaling complexes with Shc and Grb2. Curr Biol 6 4 (1996) 438-445
11. Lioubin M.N., Algate P.A., Tsai S., Carlberg K., Aebersold A., and Rohrschneider L.R. p150Ship, a signal transduction molecule with inositol polyphosphate-5-phosphatase activity. Genes Develop 10 9 (1996) 1084-1095
12. Brazil D.P., and Hemmings B.A. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 26 11 (2001) 657-664
13. Whiteman E.L., Cho H., and Birnbaum M.J. Role of Akt/protein kinase B in metabolism. Trends Endocrinol Metab 13 10 (2002) 444-451
14. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2 7 (2002) 489-501
15. Nicholson K.M., and Anderson N.G. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14 5 (2002) 381-395
16. West K.A., Castillo S.S., and Dennis P.A. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Update 5 6 (2002) 234-248
17. Parra-Bonilla G., Arboleda G., Yunis J., Solano E., Pardo R., Arango G., et al. Haplogroup analysis of the risk associated with APOE promoter polymorphisms (-219T/G, -491A/T and -427T/C) in Colombian Alzheimer's disease patients. Neurosci Lett 349 3 (2003) 159-162
18. Arboleda M.J., Lyons J.F., Kabbinavar F.F., Bray M.R., Snow B.E., Ayala R., et al. Overexpression of AKT2/protein kinase B beta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 63 1 (2003) 196-206
19. Arboleda A., Morrow P.C., Crum M.R., and Shelley II M.C. Management practices as antecedents of safety culture within the trucking industry: similarities and differences by hierarchical level. J Safety Res 34 2 (2003) 189-197
20. Yamaguchi H., and Wang H.G. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene 20 53 (2001) 7779-7786
21. Downward J. How BAD phosphorylation is good for survival. Nat Cell Biol 1 2 (1999) E33-E35
22. Cardone M.H., Roy N., Stennicke H.R., Salvesen G.S., Franke T.F., Stanbridge E., et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 282 5392 (1998) 1318-1321
23. Kozma S.C., and Thomas G. Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K. Bioessays 24 1 (2002) 65-71
24. Faridi J., Fawcett J., Wang L., and Roth R.A. Akt promotes increased mammalian cell size by stimulating protein synthesis and inhibiting protein degradation. Am J Physiol Endocrinol Metab 285 5 (2003) E964-E972
25. Inoki K., Li Y., Zhu T., Wu J., and Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4 9 (2002) 648-657
26. Tee A.R., Anjum R., and Blenis J. Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin. J Biol Chem 278 39 (2003) 37288-37296
27. McManus E.J., and Alessi D.R. TSC1-TSC2: a complex tale of PKB-mediated S6K regulation. Nat Cell Biol 4 9 (2002) E214-E216
28. Inoki K., Zhu T., and Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115 5 (2003) 577-590
29. Lee C., Kim J.S., and Waldman T. PTEN gene targeting reveals a radiation-induced size checkpoint in human cancer cells. Cancer Res 64 19 (2004) 6906-6914
30. Rosner M., Hofer K., Kubista M., and Hengstschlager M. Cell size regulation by the human TSC tumor suppressor proteins depends on PI3K and FKBP38. Oncogene 22 31 (2003) 4786-4798
31. Sun M., Wang G., Paciga J.E., Feldman R.I., Yuan Z.Q., Ma X.L., et al. AKT1/PKB alpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159 2 (2001) 431-437
32. Davies M.A., Kim S.J., Parikh N.U., Dong Z., Bucana C.D., and Gallick G.E. Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin Cancer Res 8 6 (2002) 1904-1914
33. Nesslinger N.J., Shi X.B., and deVere White R.W. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Cancer Res 63 9 (2003) 2228-2233
34. Nakatani K., Thompson D.A., Barthel A., Sakaue H., Liu W., Weigel R.J., et al. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 274 31 (1999) 21528-21532
35. Lin H.K., Yeh S., Kang H.Y., and Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 98 13 (2001) 7200-7205
36. Denmeade S.R., Lin X.S., and Isaacs J.T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 28 4 (1996) 251-265
37. Zegarra-Moro O.L., Schmidt L.J., Huang H., and Tindall D.J. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62 4 (2002) 1008-1013
38. Balk S.P. Androgen receptor as a target in androgen-independent prostate cancer. Urology 60 3 Suppl 1 (2002) 132-138 [discussion 138-9]
39. Sharma P., Veeranna, Sharma M., Amin N.D., Sihag R.K., Grant P., et al. Phosphorylation of MEK1 by cdk5/p35 down-regulates the mitogen-activated protein kinase pathway. J Biol Chem 277 1 (2002) 528-534
40. Zhou B.P., Liao Y., Xia W., Zou Y., Spohn B., and Hung M.C. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 3 11 (2001) 973-982
41. Ogawara Y., Kishishita S., Obata T., Isazawa Y., Suzuki T., Tanaka K., et al. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 277 24 (2002) 21843-21850
42. Gottlieb T.M., Leal J.F., Seger R., Taya Y., and Oren M. Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene 21 8 (2002) 1299-1303
43. Chaudhary L.R., and Hruska K.A. Inhibition of cell survival signal protein kinase B/Akt by curcumin in human prostate cancer cells. J Cell Biochem 89 1 (2003) 1-5
44. Chun K.H., Kosmeder II J.W., Sun S., Pezzuto J.M., Lotan R., Hong W.K., et al. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Instit 95 4 (2003) 291-302
45. Chinni S.R., and Sarkar F.H. Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells. Clin Cancer Res 8 4 (2002) 1228-1236
46. Yang L., Dan H.C., Sun M., Liu Q., Sun X.M., Feldman R.I., et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 64 13 (2004) 4394-4399
47. DeFeo-Jones D., Barnett S.F., Fu S., Hancock P.J., Haskell K.M., Leander K.R., et al. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther 4 2 (2005) 271-279
48. Luo Y., Shoemaker A.R., Liu X., Woods K.W., Thomas S.A., de Jong R., et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 4 6 (2005) 977-986
49. Barnett S.F., Defeo-Jones D., Fu S., Hancock P.J., Haskell K.M., Jones R.E., et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 385 Pt 2 (2005) 399-408
50. Tang HJ, Jin X, Wang S, Yang D, Cao Y, Chen J, Gossett DR, Lin J, A small molecule compound inhibits AKT pathway in ovarian cancer cell lines. Gynecol Oncol; 2005.
51. Jin X., Gossett D.R., Wang S., Yang D., Cao Y., Chen J., et al. Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells. Br J Cancer 91 10 (2004) 1808-1812
52. Tso C.L., McBride W.H., Sun J., Patel B., Tsui K.H., Paik S.H., et al. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J 6 4 (2000) 220-233
53. Zhu K., Fukasawa I., Furuno M., Inaba F., Yamazaki T., Kamemori T., et al. Inhibitory effects of herbal drugs on the growth of human ovarian cancer cell lines through the induction of apoptosis. Gynecol Oncol 97 2 (2005) 405-409
54. Le Pecq J.B., Gosse C., Nguyen Dat X., Cros S., and Paoletti C. Antitumor activity of 9-hydroxyellipticine (NSC 210717) ON L1210 mouse leukemia and the effect of route of injection. Cancer Res 36 9 Pt 1 (1976) 3067-3076
55. Sugikawa E., Tsunoda S., Nakanishi N., and Ohashi M. 9-Hydroxyellipticine alters the conformation and DNA binding characteristics of mutated p53 protein. Anticancer Res 21 4A (2001) 2671-2675
56. Chi S.G., deVere White R.W., Meyers F.J., Siders D.B., Lee F., and Gumerlock P.H. p53 in prostate cancer: frequent expressed transition mutations. J Natl Cancer Instit 86 12 (1994) 926-933